Clearside Biomedical (NASDAQ:CLSD - Get Free Report) is projected to post its quarterly earnings results after the market closes on Tuesday, March 11th. Analysts expect Clearside Biomedical to post earnings of ($0.13) per share and revenue of $0.29 million for the quarter.
Clearside Biomedical Stock Performance
Shares of NASDAQ CLSD traded down $0.05 during mid-day trading on Friday, reaching $0.93. The company had a trading volume of 132,445 shares, compared to its average volume of 393,843. The stock has a fifty day moving average of $0.96 and a two-hundred day moving average of $1.06. The company has a market capitalization of $70.37 million, a price-to-earnings ratio of -2.06 and a beta of 2.10. Clearside Biomedical has a 12-month low of $0.77 and a 12-month high of $2.12.
Wall Street Analysts Forecast Growth
Several brokerages have weighed in on CLSD. HC Wainwright reaffirmed a "buy" rating and issued a $6.00 target price on shares of Clearside Biomedical in a research report on Thursday. Chardan Capital reissued a "buy" rating and issued a $6.00 target price on shares of Clearside Biomedical in a research report on Friday, November 15th. StockNews.com raised shares of Clearside Biomedical from a "sell" rating to a "hold" rating in a research note on Thursday, December 12th. Finally, Needham & Company LLC restated a "buy" rating and set a $6.00 target price on shares of Clearside Biomedical in a report on Thursday. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Clearside Biomedical presently has an average rating of "Moderate Buy" and an average price target of $5.33.
Get Our Latest Stock Analysis on Clearside Biomedical
About Clearside Biomedical
(
Get Free Report)
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Further Reading
Before you consider Clearside Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clearside Biomedical wasn't on the list.
While Clearside Biomedical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
